Status and phase
Conditions
Treatments
About
The purpose of this study is to determine the recommended dose for the combination of dasatinib and bendamustine in chronic lymphocytic leukemia (CLL).
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Inclusion Criteria (Cohort #1):
Inclusion Criteria (Cohort #2):
Exclusion Criteria:
Primary purpose
Allocation
Interventional model
Masking
0 participants in 2 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal